KRYS vs. CRSP, IMVT, HALO, IOVA, IBRX, SWTX, IMCR, ACLX, EXEL, and RVMD
Should you be buying Krystal Biotech stock or one of its competitors? The main competitors of Krystal Biotech include CRISPR Therapeutics (CRSP), Immunovant (IMVT), Halozyme Therapeutics (HALO), Iovance Biotherapeutics (IOVA), ImmunityBio (IBRX), SpringWorks Therapeutics (SWTX), Immunocore (IMCR), Arcellx (ACLX), Exelixis (EXEL), and Revolution Medicines (RVMD). These companies are all part of the "biological products, except diagnostic" industry.
CRISPR Therapeutics (NASDAQ:CRSP) and Krystal Biotech (NASDAQ:KRYS) are both mid-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, community ranking, institutional ownership, valuation, profitability, media sentiment, analyst recommendations, earnings and dividends.
CRISPR Therapeutics received 181 more outperform votes than Krystal Biotech when rated by MarketBeat users. However, 66.83% of users gave Krystal Biotech an outperform vote while only 65.38% of users gave CRISPR Therapeutics an outperform vote.
CRISPR Therapeutics currently has a consensus target price of $73.93, suggesting a potential upside of 32.85%. Krystal Biotech has a consensus target price of $171.00, suggesting a potential upside of 10.45%. Given Krystal Biotech's higher probable upside, research analysts clearly believe CRISPR Therapeutics is more favorable than Krystal Biotech.
CRISPR Therapeutics has a beta of 1.8, indicating that its stock price is 80% more volatile than the S&P 500. Comparatively, Krystal Biotech has a beta of 0.91, indicating that its stock price is 9% less volatile than the S&P 500.
Krystal Biotech has lower revenue, but higher earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.
CRISPR Therapeutics' return on equity of -5.74% beat Krystal Biotech's return on equity.
In the previous week, CRISPR Therapeutics had 19 more articles in the media than Krystal Biotech. MarketBeat recorded 52 mentions for CRISPR Therapeutics and 33 mentions for Krystal Biotech. CRISPR Therapeutics' average media sentiment score of 0.58 beat Krystal Biotech's score of -0.03 indicating that Krystal Biotech is being referred to more favorably in the news media.
69.2% of CRISPR Therapeutics shares are owned by institutional investors. Comparatively, 86.3% of Krystal Biotech shares are owned by institutional investors. 4.1% of CRISPR Therapeutics shares are owned by company insiders. Comparatively, 14.1% of Krystal Biotech shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Summary
Krystal Biotech beats CRISPR Therapeutics on 12 of the 17 factors compared between the two stocks.
Get Krystal Biotech News Delivered to You Automatically
Sign up to receive the latest news and ratings for KRYS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding KRYS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Krystal Biotech Competitors List
Related Companies and Tools
